DK2213295T3 - Fremgangsmåde til opnåelse af data, som er nyttige til identifikation af en patient, som er udsat for risiko for at have vanskeligheder ved at opretholde en graviditet - Google Patents

Fremgangsmåde til opnåelse af data, som er nyttige til identifikation af en patient, som er udsat for risiko for at have vanskeligheder ved at opretholde en graviditet

Info

Publication number
DK2213295T3
DK2213295T3 DK10159565.0T DK10159565T DK2213295T3 DK 2213295 T3 DK2213295 T3 DK 2213295T3 DK 10159565 T DK10159565 T DK 10159565T DK 2213295 T3 DK2213295 T3 DK 2213295T3
Authority
DK
Denmark
Prior art keywords
pregnancy
difficulty
patient
identifying
risk
Prior art date
Application number
DK10159565.0T
Other languages
English (en)
Inventor
Darryl L Carter
Original Assignee
Nora Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nora Therapeutics Inc filed Critical Nora Therapeutics Inc
Application granted granted Critical
Publication of DK2213295T3 publication Critical patent/DK2213295T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
DK10159565.0T 2003-10-24 2004-10-25 Fremgangsmåde til opnåelse af data, som er nyttige til identifikation af en patient, som er udsat for risiko for at have vanskeligheder ved at opretholde en graviditet DK2213295T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51447203P 2003-10-24 2003-10-24
EP04796441A EP1682074B1 (en) 2003-10-24 2004-10-25 Compositions and methods for healthy pregnancy

Publications (1)

Publication Number Publication Date
DK2213295T3 true DK2213295T3 (da) 2013-05-06

Family

ID=34520212

Family Applications (4)

Application Number Title Priority Date Filing Date
DK04796441.6T DK1682074T3 (da) 2003-10-24 2004-10-25 Præparater og fremgangsmåder til sund graviditet
DK10159565.0T DK2213295T3 (da) 2003-10-24 2004-10-25 Fremgangsmåde til opnåelse af data, som er nyttige til identifikation af en patient, som er udsat for risiko for at have vanskeligheder ved at opretholde en graviditet
DK11178173.8T DK2441465T3 (da) 2003-10-24 2004-10-25 Præparater og fremgangsmåder til en sund graviditet
DK10155709.8T DK2198876T3 (da) 2003-10-24 2004-10-25 Fremgangsmåde til nedsættelse af sandsynligheden for implantationssvigt i et individ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04796441.6T DK1682074T3 (da) 2003-10-24 2004-10-25 Præparater og fremgangsmåder til sund graviditet

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK11178173.8T DK2441465T3 (da) 2003-10-24 2004-10-25 Præparater og fremgangsmåder til en sund graviditet
DK10155709.8T DK2198876T3 (da) 2003-10-24 2004-10-25 Fremgangsmåde til nedsættelse af sandsynligheden for implantationssvigt i et individ

Country Status (6)

Country Link
US (11) US7470662B2 (da)
EP (7) EP1682074B1 (da)
AT (1) ATE544460T1 (da)
DK (4) DK1682074T3 (da)
ES (4) ES2381884T3 (da)
WO (1) WO2005039505A2 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
EP1682074B1 (en) * 2003-10-24 2012-02-08 Nora Therapeutics, Inc. Compositions and methods for healthy pregnancy
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
EP2091555A1 (en) * 2006-12-07 2009-08-26 Schering Corporation Use of il-27 agonists to reduce immune mediated abortion
WO2009139784A1 (en) * 2008-05-13 2009-11-19 Nora Therapeutics, Inc. Human g-csf analogs and methods of making and using thereof
US20110171168A1 (en) * 2008-05-13 2011-07-14 Nora Therapeutics, Inc. Human g-csf analogs and methods of making and using thereof
CA2731827C (en) 2008-07-22 2017-11-07 Menogenix, Inc. Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump
WO2010126528A1 (en) * 2009-05-01 2010-11-04 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
EP2475127A1 (en) * 2011-01-10 2012-07-11 Panasonic Corporation Channel state information reporting for component carriers for which no channel state information was calculated
US11717499B2 (en) * 2011-06-28 2023-08-08 Sandra Eve Reznik Administration of N,N-dimethylacetamide for the treatment of preterm birth
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
WO2013113658A1 (en) * 2012-01-31 2013-08-08 Vitrolife Sweden Ab Media
US20150110751A1 (en) * 2012-05-16 2015-04-23 Kennedy Krieger Institute, Inc. Stem cells as an individualized maternal therapy for prevention of prematurity
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
SG11201501065QA (en) * 2012-09-04 2015-03-30 Pluristem Ltd Methods for prevention and treatment of preeclampsia
ITMI20121562A1 (it) * 2012-09-19 2014-03-20 Marco Sbracia Utilizzo di g-csf nella coltura in vitro di embrioni
ITMI20122063A1 (it) 2012-12-03 2014-06-04 Marco Sbracia Gm-csf per l'utilizzo nella prevenzione dell'aborto spontaneo e del fallimento dell'impianto dell'embrione
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015057724A1 (en) * 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN112716274A (zh) * 2017-08-09 2021-04-30 沙克忍者运营有限责任公司 烹饪***
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11647861B2 (en) 2020-03-30 2023-05-16 Sharkninja Operating Llc Cooking device and components thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1A (en) * 1836-07-13 John Ruggles Locomotive steam-engine for rail and other roads
US6150085A (en) 1998-09-16 2000-11-21 The United States Of America As Represented By The Secretary Of The Army Prolonged storage of red blood cells and composition
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5908763A (en) 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
UA29377C2 (uk) 1984-09-19 2000-11-15 Новартіс Аг Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів
US5888495A (en) * 1988-05-23 1999-03-30 Genetics Institute, Inc. Method of producing storage stable M-CSF lyophilizates
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US5714140A (en) * 1989-12-13 1998-02-03 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting the production of bioactive IL-1 by administering M-CSF
US5147799A (en) * 1990-04-25 1992-09-15 Isia Bursuker Repopulation of macrophages and granulocytes using transforming growth factor-beta
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5276017A (en) * 1990-09-14 1994-01-04 Trustees Of The University Of Pennsylvania Therapeutic and diagnostic applications of tropho-uteronectin (TUN) manipulation
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
DE4242919A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
CA2183266A1 (en) * 1994-02-14 1995-08-17 Richard D. Holly Hematopoietic protein and materials and methods for making it
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
WO1997044033A1 (en) 1996-05-22 1997-11-27 Smithkline Beecham Corporation Non-peptide g-csf mimetics
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5766944A (en) * 1996-12-31 1998-06-16 Ruiz; Margaret Eileen T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments
US6162417A (en) 1997-05-07 2000-12-19 Emory University Pyrrolo isoquinolines
DE69919754T2 (de) * 1998-09-30 2005-09-01 Walter Reed Army Institute Of Research Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien
US6245740B1 (en) * 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
KR100356140B1 (ko) * 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
WO2001066765A2 (en) * 2000-03-07 2001-09-13 Millennium Pharmaceuticals, Inc. 26583, a serine/threonine phosphatase and uses thereof
WO2002020767A2 (en) * 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
EP2131198B1 (en) * 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
EP2292271A3 (en) * 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
EP1682074B1 (en) 2003-10-24 2012-02-08 Nora Therapeutics, Inc. Compositions and methods for healthy pregnancy
WO2006128176A2 (en) 2005-05-26 2006-11-30 Nora Llc Composite molecules comprising g-csf function
MY150687A (en) 2006-07-21 2014-02-28 Femalon S P R L Assay and kit for predicting implantation success in assisted fertilisation

Also Published As

Publication number Publication date
US20080213211A1 (en) 2008-09-04
EP1682074A2 (en) 2006-07-26
US7700548B2 (en) 2010-04-20
EP2196210A1 (en) 2010-06-16
US20070071716A1 (en) 2007-03-29
DK2198876T3 (da) 2013-03-11
ES2381884T3 (es) 2012-06-01
US20090081160A1 (en) 2009-03-26
WO2005039505A3 (en) 2007-12-13
EP2198876B1 (en) 2012-12-05
US7470662B2 (en) 2008-12-30
ES2458219T3 (es) 2014-04-30
US8481488B2 (en) 2013-07-09
EP2213295A1 (en) 2010-08-04
US20080213301A1 (en) 2008-09-04
US20110229436A1 (en) 2011-09-22
EP1682074B1 (en) 2012-02-08
US20090028819A1 (en) 2009-01-29
EP2213295B1 (en) 2013-01-23
US20100158971A1 (en) 2010-06-24
US7824712B2 (en) 2010-11-02
US20100158972A1 (en) 2010-06-24
US20090035262A1 (en) 2009-02-05
DK2441465T3 (da) 2014-04-14
US20090035263A1 (en) 2009-02-05
EP2198875A1 (en) 2010-06-23
DK1682074T3 (da) 2012-05-29
EP2140875A1 (en) 2010-01-06
EP2441465B1 (en) 2014-01-15
US20120269763A1 (en) 2012-10-25
US7939491B2 (en) 2011-05-10
EP1682074A4 (en) 2009-07-08
EP2198876A1 (en) 2010-06-23
US7615531B2 (en) 2009-11-10
ATE544460T1 (de) 2012-02-15
WO2005039505A2 (en) 2005-05-06
ES2405255T3 (es) 2013-05-30
ES2405506T3 (es) 2013-05-31
US7744864B2 (en) 2010-06-29
EP2441465A1 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
DK2213295T3 (da) Fremgangsmåde til opnåelse af data, som er nyttige til identifikation af en patient, som er udsat for risiko for at have vanskeligheder ved at opretholde en graviditet
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
MX2007007723A (es) Un biomaterial implantable y un metodo para producirlo.
TW200714283A (en) Method and composition for treating peripheral vascular diseases
EA200500232A1 (ru) Способы диагностики и лечения преэклампсии или эклампсии
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
WO2005102193A3 (en) Placement of fasteners into bone
DE69918089D1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
ATE548025T1 (de) Inhalierbare zubereitungen zur behandlung pulmonarer hypertensie und methoden zu ihrer verwendung
ATE543463T1 (de) Prothese und einsetzsystem
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
SG148217A1 (en) Method for treating adamts-5-associated disease
IL183079A0 (en) Method and fluorinated compositions for treating amyloid-related diseases
WO2006060787A3 (en) Delaying or preventing onset of multiple sclerosis
TW200616639A (en) Methods for treating a mammal before, during and after cardiac arrest
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
ATE461693T1 (de) Verfahren zur behandlung von akuten rhinosinusitis
WO2008034071A3 (en) Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2003059245A3 (en) Method of treating asthma
NZ519722A (en) Treatment of diabetic ulcers
WO2006007422A3 (en) CaMKII/CALCIUM CHANNEL PHOSPHORYLATION-RELATED COMPOSITIONS AND METHODS
WO2005076824A3 (en) Methods of treating irritable bowel syndrome
ATE414267T1 (de) Gewebefixativzusammensetzung